-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Kestra Medical Techs, Raises Price Target to $25

Benzinga·12/15/2025 17:50:48
Listen to the news
Goldman Sachs analyst David Roman maintains Kestra Medical Techs (NASDAQ:KMTS) with a Neutral and raises the price target from $22 to $25.